期刊文献+

HPLC法测定阿折地平片含量

Determination of Azelnidipine Tablets by HPLC
暂未订购
导出
摘要 目的 建立高效液相色谱法测定阿折地平片的含量。方法 采用Diamonsil C18柱(250mm×4.6mm,5um),以磷酸盐缓冲液(磷酸二氢钠0.005mol·L^-1,磷酸氢二钠0.004mol·L^-1)-乙腈(30:70)为流动相,流速1.0mL·min^-1;检测波长256nm;柱温30℃。结果 阿折地平在2.50-40.0ug·mL^-1范围内线性关系良好,r=0.9995,高、中、低3种不同浓度的平均回收率分别为99.8%、100.2%、100.5%,RSD为0.49%、0.57%、0.64%。结论 所用方法简便、准确,可用于阿折地平片剂的质量控制。 OBJECTIVE To establish an HPLC method for determination of content in Azelnidipine Tablets. METHODS The HPLC system consisted of a Diamonsil C18 column(250mm×4. 6mm, 5um). The mobile phase was phosphate buffer (0. 005 mol · L^-1 disodium dihydrogen phosphate,0, 004 mol · L^-1 disodium hydrogen phosphate)--acetonitrile (30 : 70). The flow rate was 1, 0 mL · min^-1. The detection wavelength was 256nm. The column temperature was 30℃. RESULTS The linear range of Azelnidipine was 2. 50-40. 0ug · mL^-1( r =0. 9995). The average recovery was 99. 8 %, 100. 2 %, 100. 5 %, RSD was 0. 49%,0. 57%,0.64%. CONCLUSION The method was simple and accurate. It can be used for quality control of content in Azelnidipine Tablets.
出处 《齐鲁药事》 2008年第7期398-399,共2页 qilu pharmaceutical affairs
关键词 阿折地平片 高效液相色谱法 含量测定 Azelnidipine Tablets HPLC determination
  • 相关文献

参考文献2

二级参考文献16

  • 1中华人民共和国国家药典委员会.中国药典[S].二部.北京:化学工业出版社,2005.287.
  • 2WELLINGTON K,SCOTT LJ.Azelnidipine[J].Drugs,2003,63(23):2613-2621.
  • 3OIZUMI K,NISHINO H,MIYAKE S,et al.Hemodynamic changes following long-term administration of CS-905,a novel dihydropyridine calcium blocker,in conscious SHR[J].Jpn J Pharmacol,1990,54(1):1-6.
  • 4OIZUMI K,MIYAMOTO M,KOIKE H.Antihypertensive effect of CS-905,a novel dihydropyridine calcium blocker,in conscious hypertensive dogs[J].Jpn J Pharmacol,1990,53(2):264-266.
  • 5ARITA M,HASHIZUME T,TANIGAWA K,et al.A new caantagonist,azelnidipine,reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension:a randomized,double-blind,placebocontrolled trial[J].J Cardiovasc Pharmacol,1999,33(2):186-192.
  • 6SADA T,SAITO H.Pharmacological profiles and clinical effects of azelnidipine,a long-acting calcium channel blocker[J].Nippon Yakurigaku Zasshi,2003,122(6):539-547.
  • 7KURAMOTO K,ICHIKAWA S,HIRAI A,et al.Azelnidipine and amlodipine:a comparison of their pharmacokinetics and effects on ambulatory blood pressure[J].Hypertens Res,2003,26(3):201-208.
  • 8OIZUMI K,MIYAMOTO M,KOIKE H.Beneficial renal effects of CS-905,a novel dihydropyridine calcium blocker in SHR[J].Jpn J Pharmacol,1989,51 (4):501-508.
  • 9KANAZAWA M,KOHZUKI M,YOSHDA K,et al.Combination therapy with an angiotensin-converting enzyme (ACE)inhibitor and a calcium antagonist:beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation[J].Hypertens Res,2002,25(3):447-453.
  • 10SATOH K,YAMAMOTO A,HOSHI K,et al.Effects of azelnidipine,a dihydropyridine calcium antagonist,on myocardial stunning in dogs[J].Jpn J Pharmacol,1998,76(4):369-376.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部